In failing hearts, wall stress increases as a result of dilation of the left ventricle. Because the arrangement of muscle fascicles in the cardiac wall transmits force longitudinally, this increase in wall stress aggravates the regional difference in contractile strength around impaired muscle, which is widely distributed throughout failing hearts. Regional differences in contractile strength may cause paradoxical stretching and shortening of the impaired muscle by contractions of the neighboring more viable muscle. Results of the present study suggest that surges of Ca 2ϩ occur within the border zone between the contracting and stretched regions during the muscle relaxation and increase the duration and ventricular rate of triggered arrhythmias. Consequently, the presence of nonuniformity of muscle contraction may explain, at least in part, why life-threatening arrhythmias are prone to occur in failing hearts. See p 2711.
Outcomes of Endovascular Repair of Ruptured Descending Thoracic Aortic Aneurysms
Thoracic endovascular aortic repair has recently offered a less invasive approach, compared with traditional open surgical repair, for the management of ruptured descending thoracic aortic aneurysms. Due to the low incidence, the exact outcome of endovascular management of this emergency is not well known. In the present multicenter study, we found that endovascular repair of ruptured descending thoracic aortic aneurysms was associated with encouraging results, which appeared to be superior to the historic results of open repair. An increased mortality was observed after endovascular management of patients with hypovolemic shock and/or hemothorax at presentation. During follow-up, the incidence of endograft-related complications such as endoleak was considerable, and several patients died as a result of an infected endograft. The findings of the current study suggest that a preferential endovascular approach for the management of ruptured descending thoracic aortic aneurysms may be appropriate; however, it emphasizes the need for continued surveillance during follow-up and perhaps improvement of current endovascular devices. See p 2718.
Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial
Collateral flow to the infarct artery territory after acute myocardial infarction may be associated with improved clinical outcomes and may also impact the benefit of subsequent recanalization of an occluded infarct-related artery. To clarify the impact of collateral flow on clinical outcomes and its interaction with the impact of percutaneous coronary intervention of an occluded infarct artery, 2173 patients with total occlusion of the infarct artery 3 to 28 days after myocardial infarction from the randomized Occluded Artery Trial were analyzed as a function of angiographic collaterals at baseline angiography. The presence and importance of angiographic collaterals at baseline were generally inversely correlated with the risk of subsequent adverse clinical outcomes and specifically associated with better left ventricular function and lower prevalence of heart failure, but collateral flow was not an independent predictor of clinical outcomes, nor was there any interaction with the results of randomized treatment assignment on clinical outcomes: Late recanalization of the infarct artery in addition to medical therapy showed no benefit compared with medical therapy alone, regardless of the presence or absence of collaterals. Therefore, although collaterals may protect the myocardium against ischemia during an evolving acute myocardial infarction, the presence of collaterals after the acute phase was not an independent predictor of subsequent clinical outcomes once infarction was completed. In addition, clinical decisions in patients with recent myocardial infarction should not be based on the presence or grade of angiographic collaterals. See p 2724.
Survival of Kidney Transplantation Patients in the United States After Cardiac Valve Replacement
Valvular heart disease is common in patients with end-stage renal disease. In hemodialysis patients, use of bioprosthetic heart valves was proscribed in past American College of Cardiology/American Heart Association guidelines, reflecting a widely held (but poorly substantiated) perception that bioprosthetic valve failure mandated mechanical prosthetic valves in these patients. In 2006, revised practice guidelines rescinded the proscription. Estimated 2-year mortality of dialysis patients is 60% after heart valve replacement surgery, with no difference in survival for tissue versus nontissue valves. Data on long-term survival of kidney transplantation patients after cardiac valve replacement are few. In this study, we identified 1335 kidney transplantation patients receiving left-sided cardiac valve replacement from 1991 to 2004. Use of tissue valves increased over time (28% overall, 38% in 2000 to 2004) . Mortality risk associated with use of tissue (versus nontissue) valves was minimally reduced. In-hospital mortality was 14.0% overall, 11.4% for tissuevalve patients, and 15.0% for nontissue-valve patients (Pϭ0.09), and estimated 2-year survival was 61.5% for tissue-valve and 59.5% for nontissue-valve patients (PϭNS). The adjusted hazard ratio of death for tissue-valve versus nontissue-valve patients was 0.83 (95% confidence interval, 0.70 to 0.99). Hospitalizations for endocarditis and gastrointestinal hemorrhage were common (Ϸ5%/y) but not related to valve type. Regardless of the prosthetic valve type, overall 2-year mortality of renal transplantation patients after left-sided cardiac valvular replacement is 40%. The additional requirement for long-term anticoagulation with nontissue valves might support the preferential use of tissue valves by clinicians and their patients who wish to avoid warfarin therapy. See p 2733.
Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis
Cerebral sinus-venous thrombosis is a rare but life-threatening disease. Its clinical course is largely unknown because prospective studies with a long follow-up and the aim to assess the recurrence rate and predisposing factors of thrombosis are lacking. Our study with a median follow-up of 6 years after discontinuation of anticoagulant therapy shows that cerebral sinus-venous thrombosis recurs June 29, 2010 rarely, particularly in the first year after withdrawal of anticoagulant treatment. Although the first cerebral sinus-venous thrombosis occurs preferentially among women of reproductive age because of the strong association with the use of oral contraceptives and pregnancy, recurrences are more frequent in men because sex-related risk factors are removed and antithrombotic prophylaxis is given in high-risk situations in women with previous cerebral sinus-venous thrombosis. Patients with a first cerebral sinus-venous thrombosis are at increased risk of developing deep vein thrombosis of the lower limbs or pulmonary embolism only if they are carriers of severe thrombophilia resulting from antithrombin, protein C or protein S deficiency, anti-phospholipid antibodies, or combined abnormalities. These data suggest that these patients should be considered for anticoagulant therapy of indefinite duration. In contrast, patients with mild thrombophilia resulting from heterozygous factor V Leiden, prothrombin G20210A, or dysfibrinogenemia do not have an increased risk of recurrent venous thromboembolism and may not need long-term anticoagulant therapy. See p 2740.
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Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a vascular disorder associated with significant morbidity and mortality. Its histological hallmark is the presence of plexiform lesions. The genesis and hemodynamic effects of the lesions, however, remain unknown. To date, no small animal model of pulmonary hypertension exists that rigorously mimics the plexiform lesions found in patients with idiopathic pulmonary arterial hypertension. This study demonstrates that plexiform lesions develop in an experimental rat model of severe pulmonary arterial hypertension. In addition, this model closely mimics the pathophysiology and other occlusive vascular lesions of human pulmonary arterial hypertension. This model will facilitate investigations of the pathogenesis of pulmonary arterial hypertension, lead to better understanding of this vascular disorder, and have value for rigorous preclinical drug evaluations. See p 2747.
